

# AgnÃ©s Fernandez-Clotet

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1203249/publications.pdf>

Version: 2024-02-01

17  
papers

513  
citations

840585

11  
h-index

887953

17  
g-index

17  
all docs

17  
docs citations

17  
times ranked

711  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and Validation of a Simplified Magnetic Resonance Index of Activity for Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 432-439.e1.	0.6	113
2	Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 35-42.	0.6	57
3	Tofacitinib for the treatment of ulcerative colitis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 881-892.	1.3	46
4	Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1017-1030.	1.9	42
5	Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1492-1500.	0.6	37
6	Persistent damage on magnetic resonance enterography in patients with Crohn's disease in endoscopic remission. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1232-1241.	1.9	30
7	Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1563-1573.	1.9	29
8	JAK Inhibition: The Most Promising Agents in the IBD Pipeline?. <i>Current Pharmaceutical Design</i> , 2019, 25, 32-40.	0.9	26
9	Validation of the Simplified Magnetic Resonance Index of Activity [sMARIA] Without Gadolinium-enhanced Sequences for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1074-1081.	0.6	26
10	Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's disease. <i>United European Gastroenterology Journal</i> , 2020, 8, 1056-1066.	1.6	23
11	Dissecting Common and Unique Effects of Anti-IL23 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 441-452.	0.6	17
12	Controlling leukocyte trafficking in IBD. <i>Pharmacological Research</i> , 2020, 159, 105050.	3.1	14
13	Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 870-879.	1.9	12
14	Mesenchymal stromal cells in the treatment of perianal fistulas in Crohn's disease. <i>Immunotherapy</i> , 2018, 10, 1203-1217.	1.0	11
15	Avoiding contrast-enhanced sequences does not compromise the precision of the simplified MaRIA for the assessment of non-penetrating Crohn's disease activity. <i>European Radiology</i> , 2022, 32, 3334-3345.	2.3	11
16	Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Getecu. <i>Journal of Clinical Medicine</i> , 2021, 10, 4402.	1.0	10
17	Adherence to endoscopic surveillance for advanced lesions and colorectal cancer in inflammatory bowel disease: an AEG and GETECU collaborative cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1402-1413.	1.9	9